• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies.

作者信息

Mehta Rohtesh S, Lee Stephanie J, Gooley Ted, Thur Laurel, Dahlberg Ann, Delaney Colleen, Gyurkocza Boglarka, Vo Phuong, Deeg H Joachim, Milano Filippo

机构信息

Division of Oncology, Fred Hutchinson Cancer Center, Seattle, WA.

Department of Medicine, University of Washington, Seattle WA.

出版信息

Blood Adv. 2025 Jun 10;9(11):2691-2694. doi: 10.1182/bloodadvances.2024015392.

DOI:10.1182/bloodadvances.2024015392
PMID:39969207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12159895/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efec/12159895/400d2db15501/BLOODA_ADV-2024-015392-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efec/12159895/400d2db15501/BLOODA_ADV-2024-015392-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efec/12159895/400d2db15501/BLOODA_ADV-2024-015392-gr1.jpg

相似文献

1
Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies.基于曲奥舒凡预处理方案治疗血液系统恶性肿瘤的长期疗效及生活质量
Blood Adv. 2025 Jun 10;9(11):2691-2694. doi: 10.1182/bloodadvances.2024015392.
2
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.欧洲血液与骨髓移植学会对血液系统恶性肿瘤儿童及青少年造血干细胞移植前白消安预处理的分析
Pediatr Blood Cancer. 2016 Jan;63(1):139-48. doi: 10.1002/pbc.25764. Epub 2015 Sep 23.
3
Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies.三氧化二砷-氟达拉滨-噻替哌预处理方案在异基因造血干细胞移植治疗儿童血液系统恶性肿瘤中的应用。
Bone Marrow Transplant. 2020 Oct;55(10):1996-2007. doi: 10.1038/s41409-020-0869-6. Epub 2020 Mar 20.
4
Long-Term Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan- or Busulfan-Based Conditioning in Pediatric Patients with Acute Leukemia or Myelodysplastic Syndrome: Results of an Associazione Italiana Ematologia Oncologia Pediatrica Retrospective Study.异基因造血干细胞移植后儿童急性白血病或骨髓增生异常综合征患者应用噻替哌或白消安为基础预处理方案的长期并发症：意大利儿科血液病学和肿瘤学学会的一项回顾性研究结果。
Transplant Cell Ther. 2024 Apr;30(4):433.e1-433.e10. doi: 10.1016/j.jtct.2023.12.671. Epub 2024 Jan 2.
5
Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.基于苏消安预处理方案治疗急性髓系白血病患者的长期预后：欧洲血液与骨髓移植学会急性白血病工作组的报告
Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.
6
Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.接受基于苏消安方案预处理的儿科异基因造血移植患者的急性毒性和结局
Pediatr Hematol Oncol. 2020 Aug;37(5):355-364. doi: 10.1080/08880018.2020.1738604. Epub 2020 Mar 13.
7
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.以白消安-氟达拉滨或三氧化二砷-氟达拉滨为基础的骨髓清除性预处理方案治疗重型地中海贫血患儿。
Ann Hematol. 2022 Mar;101(3):655-665. doi: 10.1007/s00277-021-04732-4. Epub 2022 Jan 9.
8
Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.10/10 HLA 完全相同的非亲缘供者异基因 HSCT 中基于三氟柳氮的减低强度预处理的前瞻性 II 期研究治疗血液系统恶性肿瘤。
Ann Hematol. 2012 Aug;91(8):1289-97. doi: 10.1007/s00277-012-1429-y. Epub 2012 Feb 25.
9
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.曲奥舒凡/氟达拉滨：异基因移植中的一种新预处理方案。
Ann Hematol. 2004;83 Suppl 1:S70-1. doi: 10.1007/s00277-004-0850-2.
10
Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.基于三氟尿苷的预处理后造血干细胞移植的结果：临床和药代动力学分析。
Pediatr Transplant. 2024 Jun;28(4):e14780. doi: 10.1111/petr.14780.

本文引用的文献

1
Return to school practices after hematopoietic cell transplantation: a survey of transplant centers in the United States.造血细胞移植后返校实践：美国移植中心的调查。
Bone Marrow Transplant. 2024 May;59(5):653-659. doi: 10.1038/s41409-024-02239-w. Epub 2024 Feb 20.
2
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.硼替佐米联合来那度胺和地塞米松方案治疗多发性骨髓瘤的临床疗效和安全性
Am J Hematol. 2022 Aug;97(8):1023-1034. doi: 10.1002/ajh.26620. Epub 2022 Jun 8.
3
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study.
基于三氧化二砷的预处理方案对于脐血受者来说是可行且有效的：一项 2 期多中心研究。
Blood Adv. 2020 Jul 28;4(14):3302-3310. doi: 10.1182/bloodadvances.2020002222.
4
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.对于老年急性髓系白血病或骨髓增生异常综合征患者，在异基因造血干细胞移植前采用曲奥舒凡或白消安加氟达拉滨作为预处理方案（MC-FludT.14/L）：一项随机、非劣效性3期试验。
Lancet Haematol. 2020 Jan;7(1):e28-e39. doi: 10.1016/S2352-3026(19)30157-7. Epub 2019 Oct 9.
5
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植后免疫抑制成功停药的相关因素。
JAMA Oncol. 2020 Jan 1;6(1):e192974. doi: 10.1001/jamaoncol.2019.2974. Epub 2020 Jan 9.
6
Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.三氟尿苷/氟达拉滨联合或不联合全身照射的移植预处理：骨髓增生异常综合征和急性髓系白血病患者的随机 II 期试验。
Biol Blood Marrow Transplant. 2018 May;24(5):956-963. doi: 10.1016/j.bbmt.2017.12.785. Epub 2017 Dec 20.
7
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.急性髓系白血病和骨髓增生异常综合征的清髓性与减低强度造血细胞移植
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
8
Occupational status among adult survivors following allo-SCT.异基因造血干细胞移植后成年幸存者的职业状况。
Bone Marrow Transplant. 2014 Jun;49(6):836-42. doi: 10.1038/bmt.2014.26. Epub 2014 Mar 10.
9
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.三氧化二砷、氟达拉滨和 2Gy 全身照射联合异基因造血细胞移植治疗骨髓增生异常综合征和急性髓系白血病。
Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16.
10
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).造血细胞移植后妊娠：来自国际血液和骨髓移植研究中心（CIBMTR）晚期效应工作组的报告。
Biol Blood Marrow Transplant. 2011 Feb;17(2):157-66. doi: 10.1016/j.bbmt.2010.07.009. Epub 2010 Jul 24.